Family Medicine

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

An analysis of FDA Adverse Event Reporting System data suggests baloxavir marboxil has lower hepatic toxicity than oseltamivir and may be a safer option for patients with liver diseases.

A combination of telemedicine and in-person visits led to a nearly 6% increase in electronic health record work for primary care physicians.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

Current approaches to vision screening in the US may not sufficiently cater to children of all sociodemographic backgrounds.

In August 2023, 34.5% of mental health visits took place via video, and 10% of primary and subspecialty occurred via telemedicine (including video and/or telephone).

A new study reports previously unknown inherited genetic variants that contribute to glaucoma risk among more than 11,000 people of African ancestry.

For the first time, the FDA has approved a plan allowing Florida to import certain, cheaper prescription drugs from Canada.

A systematic review combined with a pair of case studies suggest men who discontinue the front-line treatment for conditions like polycythaemia vera may improve their fertility.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

The current treatment paradigm might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

Data from a nationally representative survey show that, despite most US adults agree the COVID-19 and flu vaccines are safe and effective, there is discrepancy in why some may not want one or the other.

The FDA approved zuranolone for postpartum depression in August, and the drug recently hit the market for patients this month. Experts are celebrating its delivery of care and rapid response rate.

Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.

Multinational data support the safety of drug classes like GLP-1 agonists during early relative to infant risk of major congenital malformations.

Designed to treat the acne's inflammation, bacteria and follicular hyperkeratinization, IDP-126 has shown significant efficacy compared to standard-care options already on the market.

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

An analysis of age-stratified fatty liver disease patient demographics show a surprising shift in racial/ethnic and sex trends among children and adolescents.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

New data show children with higher baseline adaptative functioning scores, as well as girls, were more likely to have nonpersistent autism spectrum disorder in later years.

Multiple cohorts of health care professions, including registered nurses and social/behavioral workers, are at greater risk of suicide than the general population, according to new data.

When cognitively healthy older adults performed a road test when taking a medicine with adverse effects, 35% of participants received a marginal/fail rating.

New data from Sweden conflict with previous register-based research showing a “substantially” increased risk of mania among antidepressant-treated pediatric patients with unipolar depression.

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.

The advisory committee's vote may trigger an FDA decision to remove more than 250 cough medicine products from the market, or require a reformulation of such items.